Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 11, 2015, Pages 1316-1328

  Karami, Azadeh ^a,b   Eyjolfsdottir, Helga ^a,b   Vijayaraghavan, Swetha ^a   Lind, Göran ^a,b   Almqvist, Per ^a,b   Kadir, Ahmadul ^a   Linderoth, Bengt ^a,b   Andreasen, Niels ^a,b   Blennow, Kaj ^c   Wall, Anders ^d   Westman, Eric ^a,b   Ferreira, Daniel ^a   Kristoffersen Wiberg, Maria ^a,b   Wahlund, Lars Olof ^a,b   Seiger, Åke ^e   Nordberg, Agneta ^a,b   Wahlberg, Lars ^f   Darreh Shori, Taher ^a,b   Eriksdotter, Maria ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e Stockholms Sjukhem   (Sweden)

^f NsGene Inc   (United States)

Author keywords

Acetyl cholinesterase; Alzheimer's disease; Amyloid ; Choline acetyltransferase; MRI; Nerve growth factor; Nicotine receptors; PET; tau

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINE ACETYLTRANSFERASE; GLUCOSE; NERVE GROWTH FACTOR; NICOTINIC RECEPTOR; TAU PROTEIN; MAPT PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CELL ENCAPSULATION; CELL THERAPY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; COGNITION; COGNITION ASSESSMENT; ENZYME ACTIVITY; FOREBRAIN; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; HUMAN; IMPLANT; IN VIVO STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGED; BRAIN; CELL TRANSPLANTATION; FEMALE; GENE THERAPY; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; SURGERY; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; CELL TRANSPLANTATION; CHOLINE O-ACETYLTRANSFERASE; COGNITION; FEMALE; GENETIC THERAPY; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; TAU PROTEINS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84947869471     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.11.008     Document Type: Article

References (58)

1. P. Davies, and A.J. Maloney Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 1976 1403
2. N.I. Bohnen, D.I. Kaufer, L.S. Ivanco, B. Lopresti, R.A. Koeppe, J.G. Davis, and et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch Neurol 60 2003 1745 1748
3. R. Pearson, K. Gatter, and T. Powell The cortical relationships of certain basal ganglia and the cholinergic basal forebrain nuclei Brain Res 261 1983 327 330
4. M. Seiler, and M.E. Schwab Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat Brain Res 300 1984 33 39
5. A. Salehi, J.D. Delcroix, and D. Swaab Alzheimer's disease and NGF signaling J Neural Transm 111 2004 323 345
6. L. Olson, L. Bäckman, T. Ebendal, M. Eriksdotter-Jönhagen, B. Hoffer, C. Humpel, and et al. Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases J Neurol 242 1994 12 15
7. M. Fahnestock, B. Michalski, B. Xu, and M.D. Coughlin The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease Mol Cell Neurosci 18 2001 210 220
8. B.J. Williams, M. Eriksdotter-Jonhagen, and A.C. Granholm Nerve growth factor in treatment and pathogenesis of Alzheimer's disease Prog Neurobiol 80 2006 114 128
9. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008;8:1703-18.
10. E.J. Mufson, J.M. Conner, and J.H. Kordower Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis Neuroreport 6 1995 1063 1066
11. E.J. Mufson, M.D. Ikonomovic, S.D. Styren, S.E. Counts, J. Wuu, S. Leurgans, and et al. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease Arch Neurol 60 2003 1143 1148
12. A. Salehi, J. Verhaagen, P. Dijkhuizen, and D. Swaab Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease Neuroscience 75 1996 373 387
13. A.C. Cuello, M.A. Bruno, S. Allard, W. Leon, and M.F. Iulita Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation J Mol Neurosci 40 2010 230 235
14. S. Capsoni, S. Giannotta, and A. Cattaneo Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice Proc Natl Acad Sci U S A 99 2002 12432 12437
15. L.U. Wahlberg, G. Lind, P.M. Almqvist, P. Kusk, J. Tornoe, B. Juliusson, and et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery J Neurosurg 117 2012 340 347
16. M. Eriksdotter-Jonhagen, B. Linderoth, G. Lind, L. Aladellie, O. Almkvist, N. Andreasen, and et al. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease Dement Geriatr Cogn Disord 33 2012 18 28
17. S. Vijayaraghavan, A. Karami, S. Aeinehband, H. Behbahani, A. Grandien, B. Nilsson, and et al. Regulated extracellular choline acetyltransferase activity - the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway PLoS One 8 2013 e65936
18. T. Darreh-Shori, A. Kadir, O. Almkvist, M. Grut, A. Wall, G. Blomquist, and et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine Neurobiol Aging 29 2008 168 184
19. A. Olsson, H. Vanderstichele, N. Andreasen, G. De Meyer, A. Wallin, B. Holmberg, and et al. Simultaneous measurement of {beta}-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345
20. H. Lundqvist, A. Nordberg, P. Hartvig, and B. Långström (S)-(-)-[11C] nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain Alzheimer Dis Assoc Disord 12 1998 238 246
21. A. Nordberg, H. Lundqvist, P. Hartvig, A. Lilja, and B. Långström Kinetic analysis of regional (s)(-) 11c-nicotine binding in normal and Alzheimer brains in vivo assessment using positron emission tomography Alzheimer Dis Assoc Disord 9 1995 21 27
22. C.S. Patlak, R.G. Blasberg, and J.D. Fenstermacher Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1983 1 7
23. A. Kadir, T. Darreh-Shori, O. Almkvist, A. Wall, B. Langstrom, and A. Nordberg Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET Psychopharmacology (Berl) 191 2007 1005 1014
24. A. Gjedde Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination Brain Res 257 1982 237 274
25. B. Fischl, D.H. Salat, E. Busa, M. Albert, M. Dieterich, C. Haselgrove, and et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain Neuron 33 2002 341 355
26. B. Fischl, A. Van Der Kouwe, C. Destrieux, E. Halgren, F. Ségonne, D.H. Salat, and et al. Automatically parcellating the human cerebral cortex Cereb Cortex 14 2004 11 22
27. E. Westman, C. Aguilar, J.S. Muehlboeck, and A. Simmons Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment Brain Topogr 26 2013 9 23
28. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
29. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, M. Grundman, and et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope Alzheimer Dis Assoc Disord 11 1997 S13 S21
30. L. Han, M. Cole, F. Bellavance, J. McCusker, and F. Primeau Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis Int Psychogeriatr 12 2000 231 247
31. O.L. Lopez, J.T. Becker, S. Wisniewski, J. Saxton, D.I. Kaufer, and S.T. DeKosky Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease J Neurol Neurosurg Psychiatry 72 2002 310 314
32. D. Ferreira, E. Westman, H. Eyjolfsdottir, P. Almqvist, G. Lind, B. Linderoth, and et al. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor J Alzheimers Dis 43 2015 1059 1072
33. T. Dobransky, and R.J. Rylett A model for dynamic regulation of choline acetyltransferase by phosphorylation J Neurochem 95 2005 305 313
34. A. Nordberg, T. Darreh-Shori, E. Peskind, H. Soininen, M. Mousavi, G. Eagle, and et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients Curr Alzheimer Res 6 2009 4 14
35. T. Darreh-Shori, S. Brimijoin, A. Kadir, O. Almkvist, and A. Nordberg Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE [epsilon] 4 allele, in relation to cognitive function and cerebral glucose metabolism Neurobiol Dis 24 2006 326 333
36. A. Nordberg, and A.L. Svensson Cholinesterase inhibitors in the treatment of Alzheimers disease: a comparison of tolerability and pharmacology Drug Saf 19 1998 465 480
37. T. Darreh-Shori, L. Meurling, T. Pettersson, K. Hugosson, E. Hellström-Lindahl, N. Andreasen, and et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment J Neural Transm 113 2006 1791 1801
38. E.K. PERRY, R. Perry, G. Blessed, and B. Tomlinson Changes in brain cholinesterases in senile dementia of Alzheimer type Neuropathol Appl Neurobiol 4 1978 273 277
39. J. Rinne, V. Kaasinen, T. Järvenpää, K. Någren, A. Roivainen, M. Yu, and et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease J Neurol Neurosurg Psychiatry 74 2003 113 115
40. D.E. Kuhl, R.A. Koeppe, J.A. Fessler, S. Minoshima, R.J. Ackermann, J.E. Carey, and et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM J Nucl Med 35 1994 405 410
41. M. Iyo, H. Namba, K. Fukushi, H. Shinotoh, S. Nagatsuka, T. Suhara, and et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease Lancet 349 1997 1805 1809
42. K. Herholz, B. Bauer, K. Wienhard, L. Kracht, R. Mielke, O. Lenz, and et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism J Neural Transm 107 2000 1457 1468
43. H. Soininen, T. Halonen, and P. Riekkinen Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type Acta Neurol Scand 64 1981 217 224
44. M. Appleyard, A. Smith, P. Berman, G. Wilcock, M. Esiri, D. Neary, and et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type Brain 110 1987 1309 1322
45. M. Schwab, U. Otten, Y. Agid, and H. Thoenen Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra Brain Res 168 1979 473 483
46. H. Gnahn, F. Hefti, R. Heumann, M. Schwab, and H. Thoenen NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Brain Res 285 1983 45 52
47. P. Honegger, and D. Lenoir Nerve growth factor (NGF) stimulation of cholinergic telencephalic neurons in aggregating cell cultures Brain Res 255 1982 229 238
48. W.C. Mobley, J.L. Rutkowski, G.I. Tennekoon, J. Gemski, K. Buchanan, and M.V. Johnston Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons Mol Brain Res 1 1986 53 62
49. M.H. Tuszynski, L. Thal, M. Pay, and D.P. Salmon A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat Med 11 2005 551 555
50. L. Olson, A. Nordberg, H. Von Holst, L. Bäckman, T. Ebendal, I. Alafuzoff, and et al. Nerve growth factor affects 11 C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report) J Neural Transm Park Dis Dement Sect 4 1992 79 95
51. M. Eriksdotter Jönhagen, A. Nordberg, K. Amberla, L. Bäckman, T. Ebendal, B. Meyerson, and et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease Dement Geriatr Cogn Disord 9 1998 246 257
52. S. Allen, S. MacGowan, J. Treanor, R. Feeney, G. Wilcock, and D. Dawbarn Normal [beta]-NGF content in Alzheimer's disease cerebral cortex and hippocampus Neurosci Lett 131 1991 135 139
53. A. Cuello, A. Bruno, and K. Bell NGF-cholinergic dependency in brain aging, MCI and Alzheimers disease Curr Alzheimer Res 4 2007 351 358
54. L. Olson NGF and the treatment of Alzheimer's disease Exp Neurol 124 1993 5 15
55. B. Oderfeld-Nowak, and A. Bacia Expression of astroglial nerve growth factor in damaged brain Acta Neurobiol Exp (Wars) 54 1994 73 80
56. W.J. Friedman, S. Thakur, L. Seidman, and A.B. Rabson Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NFκB J Biol Chem 271 1996 31115 31120
57. G.M. Jonakait, L. Pratt, G. Acevedo, and L. Ni Microglial regulation of cholinergic differentiation in the basal forebrain Dev Neurobiol 72 2012 857 864
58. T. Darreh-Shori, S. Vijayaraghavan, S. Aeinehband, F. Piehl, R.P. Lindblom, B. Nilsson, and et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease Neurobiol Aging 34 2013 2465 2481